Golden Opportunities Fund exits CanniMed Therapeutics with massive return

Photo of author

By Ted Liu

Golden Opportunities Fund Inc. (GOF), a retail fund managed by Westcap Mgt, has sold 4,020,292 common shares of CanniMed Therapeutics Inc. (TSX: CMED) to Aurora Cannabis Inc. (TSX: ACB; OTCQB: ACBFF; FSE: 21P; WKN: A1C4WM) pursuant to Aurora’s take-over bid for all of the issued and outstanding common shares.

On January 24, 2018, Aurora Cannabis agreed to acquire CanniMed with CanniMed shareholders receiving 3.40 Aurora shares for each share held, or a combination of cash and shares subject to pro-ration with the maximum aggregate cash consideration of $140 million.

Aurora Cannabis completed the acquisition on March 15, 2018. Aurora Cannabis stock closed $11.25 on March 15, implying a value of $38.25 for each CanniMed shares.

At $38.25, GOF holding in CanniMed is valued at approximately $153.78 million, representing a return of [mepr-active rule=”374″ ifallowed=”hide”]#SUBSCRIBERS ONLY CONTENT
Where and how did you get your news? Subscribe today to see our research on this and all other subscriber ONLY news. See what you have been missing and be informed!#
[/mepr-active][mepr-active rule=”374″]28.13 times of its investment costs of $5.467 million. [/mepr-active]

photo credit: CanniMed

News Release

Golden Opportunities Fund Inc. – Early Warning News Release

SASKATOON, March 15, 2018 /CNW/ – Golden Opportunities Fund Inc. (the “Fund”) pursuant to the early warning requirements of National Instrument 62-103 and 62-104, announced today it sold 4,020,292 common shares (“Common Shares”) of CanniMed Therapeutics Inc. (“CanniMed”), representing all of the Common Shares that it previously owned, to Aurora Cannabis Inc. (“Aurora”) pursuant to Aurora’s take-over bid for all of the issued and outstanding Common Shares.

As a result of the sale, the Fund’s direct and indirect beneficial ownership and control over Common Shares was reduced from approximately 16.4% percent of the issued and outstanding Common Shares to zero percent of the issued and outstanding Common Shares.

The Fund sold the Common Shares to realize a gain on its investment in Common Shares. The Fund has no intention of acquiring any Common Shares in the future.

The head office of CanniMed is located at 1 Plant Technology Road, Box 19A, RR #5, Saskatoon, Saskatchewan S7K 3J8.

SOURCE Golden Opportunities Fund Inc.

For further information: and to obtain a copy of the early warning report to be filed under applicable Canadian securities laws in connection with the foregoing matters, please see the profile of CanniMed at or contact the Fund at (306) 652-5557.